XML 105 R23.htm IDEA: XBRL DOCUMENT v3.20.1
SHAREHOLDERS' EQUITY
 3 Months Ended
Mar. 31, 2020
Equity [Abstract]  
SHAREHOLDERS' EQUITY
NOTE 15. SHAREHOLDERS’ EQUITY
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
Three months ended March 31
(In millions)
2020

 
2019

 
 
 
 
Beginning balance
$
61

 
$
(39
)
Other comprehensive income (loss) (OCI) before reclassifications – net of deferred taxes of $0 and $38(a)
6

 
28

Reclassifications from OCI – net of deferred taxes of $(12) and $(1)
(47
)
 
(4
)
Other comprehensive income (loss)
(41
)
 
24

Less OCI attributable to noncontrolling interests
—

 
1

Investment securities ending balance
$
20

 
$
(16
)
 
 
 
 
Beginning balance
$
(4,818
)
 
$
(6,134
)
OCI before reclassifications – net of deferred taxes of $(5) and $26
(554
)
 
307

Reclassifications from OCI – net of deferred taxes of $0 and $(4)(b)
690

 
117

Other comprehensive income (loss)
135

 
423

Less OCI attributable to noncontrolling interests
2

 
100

Currency translation adjustments ending balance
$
(4,685
)
 
$
(5,810
)
 
 
 
 
Beginning balance
$
49

 
$
13

OCI before reclassifications – net of deferred taxes of $(45) and $11
(262
)
 
34

Reclassifications from OCI – net of deferred taxes of $8 and $(4)(b)
51

 
3

Other comprehensive income (loss)
(211
)
 
38

Less OCI attributable to noncontrolling interests
—

 
2

Cash flow hedges ending balance
$
(163
)
 
$
49

 
 
 
 
Beginning balance
$
(7,024
)
 
$
(8,254
)
OCI before reclassifications – net of deferred taxes of $30 and $48
219

 
(116
)
Reclassifications from OCI – net of deferred taxes of $239 and $183(b)
817

 
662

Other comprehensive income (loss)
1,035

 
545

Less OCI attributable to noncontrolling interests
3

 
(2
)
Benefit plans ending balance
$
(5,991
)
 
$
(7,708
)
 
 
 
 
Accumulated other comprehensive income (loss) at March 31
$
(10,819
)
 
$
(13,485
)

(a) Included adjustments of $1,267 million and $(957) million for the three months ended March 31, 2020 and 2019, respectively related to insurance liabilities and annuity benefits in our run-off insurance operations to reflect the effects that would have been recognized had the related unrealized investment security gains been realized. See Note 12 for further information.
(b) Included $836 million, including currency translation of $688 million, net of taxes, for the three months ended March 31, 2020, related to the sale of our BioPharma business within our Healthcare segment.

In 2016, we issued $5,694 million of GE Series D preferred stock, which are callable on January 21, 2021. In addition to Series D, $250 million of existing GE Series A, B and C preferred stock are also outstanding. The total carrying value of GE preferred stock at March 31, 2020 was $5,782 million and will increase to $5,944 million by the respective call dates through periodic accretion. See our Annual Report on Form 10-K for the year ended December 31, 2019 for further information.

Noncontrolling interests in equity of consolidated affiliates amounted to $1,575 million and $1,545 million at March 31, 2020 and December 31, 2019, respectively. Net earnings (loss) attributable to noncontrolling interests were $7 million and $30 million for the three months ended March 31, 2020 and 2019, respectively. Dividends attributable to noncontrolling interests were $(3) million and $(106) million for the three months ended March 31, 2020 and 2019, respectively.

Redeemable noncontrolling interests presented within All other liabilities in our consolidated Statement of Financial Position include common shares issued by our affiliates that are redeemable at the option of the holder of those interests and amounted to $470 million and $439 million as of March 31, 2020 and December 31, 2019, respectively. Net earnings (loss) attributable to redeemable noncontrolling interests was $27 million and $27 million for the three months ended March 31, 2020 and 2019, respectively.